엠파글리플로진

한글명:엠파글리플로진

카스 번호864070-44-0

상품명:Empagliflozin

CBNumberCB52627802

분자식C23H27ClO7

포뮬러 무게450.91

MOL 파일864070-44-0.mol

동의어(한글)

엠파글리플로진

화학적 성질

끓는 점	665℃
밀도	1.398
인화점	356℃
저장 조건	2-8°C
용해도	insoluble in H2O; ≥20.75 mg/mL in DMSO; ≥7.06 mg/mL in EtOH with ultrasonic
물리적 상태	고체
물리적 상태	단단한 모양
산도 계수 (pKa)	13.23±0.70(Predicted)
색상	하얀색
안정성	흡습성
InChIKey	OBWASQILIWPZMG-QZMOQZSNSA-N
SMILES	C1=C(CC2=CC([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)=CC=C2Cl)C=CC(O[C@H]2CCOC2)=C1

그림문자(GHS)

엠파글리플로진 화학적 특성, 용도, 생산

개요
Empagliflozin (상품명 Jardiance)는 2014년에 성인에 있는 타입-2 당뇨병의 처리를 위해 승인되는 gliflozin 종류의 약 입니다. 그것은 Boehringer Ingelheim에 의해 Eli Lilly Company 개발되고.
용도
Empagliflozin는 나트륨 포도당 CO 운송업자 2 (SGLT-2)의 억제물, 및 혈액에 있는 원인 설탕 배설되고 신장에 의해 소변에서 삭제되기위하여입니다.
개요
Empagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, was originally discovered by Boehringer Ingelheim and codeveloped and co-marketed through research collaboration with Eli Lilly and Co. It was first approved by European Medicine Agency (EMA) in May 2014, followed by the approval of the US FDA in August 2014. SGLT2 inhibitors are anewclass of glucose-lowering agents developed for the treatment of type 2 diabetes mellitus, which have a mechanism of action that is independent of pancreatic b-cell function or the degree of insulin resistance. Consequently, SGLT2 inhibitors have the potential to be of use not only as standalone therapy but also in combination with any of the existing classes of glucose-lowering agents, including insulin. Empagliflozin selectively inhibits SGLT2, which in turn prevents glucose reabsorption by excreting excess glucose in the urine.
용도
Empagliflozin is a novel, potent and selective SGLT-2 inhibitor, improves glycaemic control and features of metabolic syndrome in diabetic rats.
정의
ChEBI: Empagliflozin is a C-glycosyl compound consisting of a beta-glucosyl residue having a (4-chloro-3-{4-[(3S)-tetrahydrofuran-3-yloxy]benzyl}phenyl group at the anomeric centre. A sodium-glucose co-transporter 2 inhibitor used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It has a role as a sodium-glucose transport protein subtype 2 inhibitor and a hypoglycemic agent. It is a C-glycosyl compound, an aromatic ether, a tetrahydrofuryl ether and a member of monochlorobenzenes.
Mode of action
Empagliflozin is an orally available competitive inhibitor of sodium-glucose co-transporter 2 (SGLT2; SLC5A2) with antihyperglycemic activity. Upon oral administration, empagliflozin selectively and potently inhibits SGLT2 in the kidneys, thereby suppressing the reabsorption of glucose in the proximal tubule. Inhibition of SGLT2 increases urinary glucose excretion by the kidneys, resulting in a reduction of plasma glucose levels in an insulin-independent manner. Inhibition of SGLT2 in the kidneys also suppresses the renal reabsorption of 1,5-anhydroglucitol (1,5AG). This lowers serum 1,5AG and neutrophil 1,5-anhydroglucitol-6-phosphate (1,5AG6P) levels, which may improve neutropenia and neutrophil dysfunction in patients with glycogen storage disease type Ib (GSD Ib). SGLT2, a transport protein exclusively expressed in the proximal renal tubules, mediates approximately 90% of renal glucose reabsorption from tubular fluid.
pubchem.ncbi.nlm.nih.gov/compound/Empagliflozin

엠파글리플로진 준비 용품 및 원자재

엠파글리플로진 공급 업체

Send Inquriy